Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment

Open access

Abstract

BACKGROUND: Tasquinimod (a quinoline-3-carboxyamide) is a small molecule immunotherapy with demonstrated effects on the tumor microenvironment (TME) involving immunomodulation, anti-angiogenesis and inhibition of metastasis. A target molecule of tasquinimod is the inflammatory protein S100A9 which has been shown to affect the accumulation and function of suppressive myeloid cell subsets in tumors. Given the major impact of myeloid cells to the tumor microenvironment, manipulation of this cell compartment is a desirable goal in cancer therapeutics. METHODS: To understand the consequences of tasquinimod treatment on the TME, we evaluated early treatment effects in tumor infiltrating myeloid cells. Cellular phenotypes were studied by flow cytometry while gene expression both in tumor tissue and in isolated CD11b(+) cells or tumor cells were measured by real time-PCR. Effects on angiogenesis were monitored by changes in CD31 levels and by gene expression in tumor tissue. Effects on cytokine levels in tumor tissue and serum were determined by multiplex analysis. RESULTS: The MC38-C215 colon carcinoma tumors showed a substantial infiltration of primarily myeloid cells that were dominated by Ly6C(low)F4/80(+)CD206(+) M2-polarized tumor associated macrophages (TAMs), an immuno-suppressive and pro-angiogenic cell population. Here, we show that tasquinimod treatment induces an anti-tumor effect which is subsequent to a reduction in tumor infiltrating CD206(+) M2 macrophages and a simultaneous increase in M1 macrophages expressing MHC class II and CD86. The tasquinimod-induced changes in TAM polarization were evident within 24 h of exposure, emphasizing the ability of tasquinimod to rapidly reprogram the tumor microenvironment. This change in the tumor associated myeloid compartment preceded an increased IL12-production within the tumor and a decrease in tumor neovascularization. The switch in TAM polarization by tasquinimod was confirmed in the 4T1 breast cancer model where tasquinimod also reduce lung metastasis development. CONCLUSION: Our data show that tasquinimod affects tumor infiltrating myeloid cells early after exposure, leading to a change in phenotype from pro-angiogenic and immunosuppressive M2-like TAMs to pro-inflammatory M1-like macrophages. These changes are consistent with the effects of tasquinimod seen on tumor vascularization, immune suppression and metastasis giving further insights to the anti-tumor mechanism of action of tasquinimod.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s40425-015-0098-5

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Tasquinimod impairs tumor growth in vivo and reduces the microvascular density in MC38-C215 tumors. a Wild type mice were inoculated s.c. with 0.5 × 106 MC38-C215 cells. Treatment with tasquinimod (30 mg/kg ad lib.) was initiated on the day of tumor inoculation and continued throughout the experiment. Tumor volumes (left panel) were measured every 2-3 days from day 7 and the experiment was terminated on day 14 (*p = 0.029; two-way ANOVA, Error bars indicate s.e.m) and tumor weights (right panel) at the end of experiment (*p < 0.05; Mann Whitney). b No effect on MC38-C215 proliferation in vitro. MC38-C215 cancer cells (5000 cells/well) were seeded in 96 well plates and the cultured cells treated with tasquinimod for 72 h under either normoxic (left panel) or hypoxic (right panel) growth conditions. Viability was determined by MTT assay at the end of incubation. c CD31 staining is significantly different between tumors from control and tasquinimod treated animals: Left-control group tumor, right-tasquinimod group tumor. Vascular density determined as percentage of stained area compared to total tumor area (* p < 0.05; Mann Whitney, Error bars indicate s.e.m)
Fig. 1 Tasquinimod impairs tumor growth in vivo and reduces the microvascular density in MC38-C215 tumors. a Wild type mice were inoculated s.c. with 0.5 × 106 MC38-C215 cells. Treatment with tasquinimod (30 mg/kg ad lib.) was initiated on the day of tumor inoculation and continued throughout the experiment. Tumor volumes (left panel) were measured every 2-3 days from day 7 and the experiment was terminated on day 14 (*p = 0.029; two-way ANOVA, Error bars indicate s.e.m) and tumor weights (right panel) at the end of experiment (*p < 0.05; Mann Whitney). b No effect on MC38-C215 proliferation in vitro. MC38-C215 cancer cells (5000 cells/well) were seeded in 96 well plates and the cultured cells treated with tasquinimod for 72 h under either normoxic (left panel) or hypoxic (right panel) growth conditions. Viability was determined by MTT assay at the end of incubation. c CD31 staining is significantly different between tumors from control and tasquinimod treated animals: Left-control group tumor, right-tasquinimod group tumor. Vascular density determined as percentage of stained area compared to total tumor area (* p < 0.05; Mann Whitney, Error bars indicate s.e.m)CC BY · PubMed Central
Fig. 2 CD11b+F4/80+ infiltrating cells are functionally skewed from a pro-tumor CD206+ M2 phenotype into a CD206− anti-tumor M1 phenotype after tasquinimod treatment. Modulation of myeloid CD11b+ subpopulations in MC38 tumors by tasquinimod. a Percent CD11b+ cells of infiltrating cells, b representative FACS plots F4/80+CD206+ staining of tumor infiltrating CD11b+ cells, c F4/80+ cells as frequency of total CD11b+ cells, d frequency of CD206+ cells in tumors ± tasquinimod treatment (**p < 0.01; two-way ANOVA, Error bars indicate s.e.m) and e frequency of Ly6ChighLy6G− and Ly6G+ cell populations in tumor. f Up-regulation of M1 markers and down-regulation of M2 markers in infiltrating CD11b+F4/80+ after tasquinimod treatment. Tumor infiltrating CD11b+F4/80+ cells were isolated from MC38-C215 tumors at day 14, FACS-sorted and qRT-PCR was performed on the indicated genes. g Infiltrating F4/80+ cells are less immune suppressive after tasquinimod treatment. CD4+ T cells were stimulated with αCD3 and α CD28 in the presence of F4/80+ cells at indicated ratios (F4/80:CD4) and proliferation was measured by 3H-thymidine incorporation (**p < 0.01 and ***p < 0.001; t-test, Error bars indicate s.e.m)
Fig. 2 CD11b+F4/80+ infiltrating cells are functionally skewed from a pro-tumor CD206+ M2 phenotype into a CD206− anti-tumor M1 phenotype after tasquinimod treatment. Modulation of myeloid CD11b+ subpopulations in MC38 tumors by tasquinimod. a Percent CD11b+ cells of infiltrating cells, b representative FACS plots F4/80+CD206+ staining of tumor infiltrating CD11b+ cells, c F4/80+ cells as frequency of total CD11b+ cells, d frequency of CD206+ cells in tumors ± tasquinimod treatment (**p < 0.01; two-way ANOVA, Error bars indicate s.e.m) and e frequency of Ly6ChighLy6G− and Ly6G+ cell populations in tumor. f Up-regulation of M1 markers and down-regulation of M2 markers in infiltrating CD11b+F4/80+ after tasquinimod treatment. Tumor infiltrating CD11b+F4/80+ cells were isolated from MC38-C215 tumors at day 14, FACS-sorted and qRT-PCR was performed on the indicated genes. g Infiltrating F4/80+ cells are less immune suppressive after tasquinimod treatment. CD4+ T cells were stimulated with αCD3 and α CD28 in the presence of F4/80+ cells at indicated ratios (F4/80:CD4) and proliferation was measured by 3H-thymidine incorporation (**p < 0.01 and ***p < 0.001; t-test, Error bars indicate s.e.m)CC BY · PubMed Central
Fig. 3 Tasquinimod induces tumor immunomodulation and inhibits tumor angiogenesis within one week of exposure. a CD31 staining of tumors from control and tasquinimod treated animals. Mice were treated for 1, 5 or 7 days with tasquinimod (p.o.; 30 mg/kg/day). b Hypoxia-induced expression of Hif-1α controlled genes in tumor samples; SemaphorinB (left panel) and Glut-1 (right panel) after 7 days of exposure. c Time study of mRNA expression in tumors treated with tasquinimod for 1 up to 7 days of exposure CD206 (Mrc1) (left panel) and Nos2 (right panel) (versus control; * p < 0.05; ** p < 0.01 and *** p < 0.001; One way ANOVA with Dunnetts multiple comparison test, Error bars indicate s.e.m)
Fig. 3 Tasquinimod induces tumor immunomodulation and inhibits tumor angiogenesis within one week of exposure. a CD31 staining of tumors from control and tasquinimod treated animals. Mice were treated for 1, 5 or 7 days with tasquinimod (p.o.; 30 mg/kg/day). b Hypoxia-induced expression of Hif-1α controlled genes in tumor samples; SemaphorinB (left panel) and Glut-1 (right panel) after 7 days of exposure. c Time study of mRNA expression in tumors treated with tasquinimod for 1 up to 7 days of exposure CD206 (Mrc1) (left panel) and Nos2 (right panel) (versus control; * p < 0.05; ** p < 0.01 and *** p < 0.001; One way ANOVA with Dunnetts multiple comparison test, Error bars indicate s.e.m)CC BY · PubMed Central
Fig. 4 M1 macrophages, induced by tasquinimod modulates the expression of different angiogenic factors. a Median Fluorescence Intensity (MFI)values of CD206, MHC-II and CD86 cell surface expression evaluated by flow cytometry on isolated tumor infiltrating CD11b+ cells gated on the F4/80high population after 1 and 3 days of in vivo exposure to tasquinimod. Results from one out of three representative experiments are shown. b Up-regulation of M1 genes Nos2 (iNos) and Il-12β, and down-regulation of M2 genes CD206, Arg-1 and Il-10 mRNA expression in isolated tumor infiltrating CD11b+ cells after 1 and 3 days of in vivo exposure to tasquinimod. c Changes of pro-angiogenic genes Vegfa, Vegfc, Fgf2, Nrp1 and Il-6 mRNA expression in isolated tumor infiltrating CD11b+ cells after 1 and 3 days of in vivo exposure to tasquinimod (versus control; * p < 0.05; ** p < 0.01 and *** p < 0.001; One way ANOVA with Dunnetts multiple comparison test, Error bars indicate s.e.m)
Fig. 4 M1 macrophages, induced by tasquinimod modulates the expression of different angiogenic factors. a Median Fluorescence Intensity (MFI)values of CD206, MHC-II and CD86 cell surface expression evaluated by flow cytometry on isolated tumor infiltrating CD11b+ cells gated on the F4/80high population after 1 and 3 days of in vivo exposure to tasquinimod. Results from one out of three representative experiments are shown. b Up-regulation of M1 genes Nos2 (iNos) and Il-12β, and down-regulation of M2 genes CD206, Arg-1 and Il-10 mRNA expression in isolated tumor infiltrating CD11b+ cells after 1 and 3 days of in vivo exposure to tasquinimod. c Changes of pro-angiogenic genes Vegfa, Vegfc, Fgf2, Nrp1 and Il-6 mRNA expression in isolated tumor infiltrating CD11b+ cells after 1 and 3 days of in vivo exposure to tasquinimod (versus control; * p < 0.05; ** p < 0.01 and *** p < 0.001; One way ANOVA with Dunnetts multiple comparison test, Error bars indicate s.e.m)CC BY · PubMed Central
Fig. 5 Tasquinimod-induced functional changes in tumor derived CD11b+. a Changes of Arg-1 and Il-12β mRNA levels in isolated tumor infiltrating CD11b+ cells stimulated with LPS/IFNγ and cultured ex vivo for 24 h. Results from one out of three representative experiments are shown (* p < 0.05; t-test, Error bars indicate s.e.m). b IL-12(p40) cytokine production of tumor lysates prepared from treated and non-treated tumors (*p < 0.05 Jonckheere-Terpstra test; Error bars indicate s.e.m)
Fig. 5 Tasquinimod-induced functional changes in tumor derived CD11b+. a Changes of Arg-1 and Il-12β mRNA levels in isolated tumor infiltrating CD11b+ cells stimulated with LPS/IFNγ and cultured ex vivo for 24 h. Results from one out of three representative experiments are shown (* p < 0.05; t-test, Error bars indicate s.e.m). b IL-12(p40) cytokine production of tumor lysates prepared from treated and non-treated tumors (*p < 0.05 Jonckheere-Terpstra test; Error bars indicate s.e.m)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 55 references

Cited by

See all 78

Metadata

Authors
Olsson, A., Nakhlé, J., Sundstedt, A., Plas, P., Bauchet, A.-L., Pierron, V., Bruetschy, L., Deronic, A., Törngren, M., Liberg, D., Schmidlin, F., & Leanderson, T.
Affiliations
  • Active Biotech (Sweden) (SE)
  • Ipsen (France) (FR)
  • Lund University (SE)
Corresponding author
  • Olsson, Anders
  • Schmidlin, Fabien
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2015-12
Volume
3
Issue
1
Pages
53-53
ISSN
2051-1426 (ISSN-L)
OpenAlex
W2206870401
Cited by
78
References
55
Citations by year
2026: 5 · 2025: 14 · 2024: 11 · 2023: 7 · 2022: 6 · 2021: 6 · 2020: 7 · 2019: 2 · 2018: 2 · 2017: 10 · 2016: 8
FWCI
3.29
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • creativecommons.org/licenses/by/4.0/ (tdm)
Locations
  • Journal for ImmunoTherapy of Cancer (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
Cancerfonden
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Keywords
tasquinimod, tumor-associated macrophages, macrophage polarization, M1/M2 macrophages, tumor microenvironment, S100A9, tumor-infiltrating myeloid cells, tumor angiogenesis, IL-12, tumor immunosuppression, lung metastasis, colon cancer, breast cancer, CD206, CD86, MHC class II

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. https://app.cochat.ai/papers/10.1186/s40425-015-0098-5
The paper
Olsson, A., Nakhlé, J., Sundstedt, A., Plas, P., Bauchet, A.-L., Pierron, V., Bruetschy, L., Deronic, A., Törngren, M., Liberg, D., Schmidlin, F., & Leanderson, T. (2015). Tasquinimod triggers an early change in the polarization of tumor associated macrophages in the tumor microenvironment. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1186/s40425-015-0098-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.